Device for sound blood

The invention relates to medicine, namely to efferent therapy and neurology, and can be used when conducting lioresalbuy in patients with pathology of the Central nervous system

The invention relates to medicine, namely to gynecology, and can be used for the treatment of patients with common process of ovarian cancer with extensive metastasis

The invention relates to medicine, namely to oncourology, and can be used to treat patients with renal cell carcinoma at different stages of the neoplastic process

The invention relates to medicine, namely to Oncology, and can be used in the treatment of breast cancer

The invention relates to medicine, namely to oncourology, and can be used to treat patients with cancer at different stages of the neoplastic process

The invention relates to medicine, transfusion medicine and can be used as cryoprecipitates

The invention relates to medicine, namely to Oncology, and can be used to treat prostate cancer

The invention relates to medicine, namely to Oncology, and can be used in the treatment of locally advanced lung cancer

The invention relates to medicine, namely to obstetrics and urology

The invention relates to medicine, namely to Oncology, and can be used in the treatment of malignant soft tissue tumors with an unfavorable course of the disease

The present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1^st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5^th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B₁₂ solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

Invention relates to a method for treatment of chronic lympholeukosis. Method involves intravenous drop and jet administration of antitumor chemopreparations and carrying out the autochemotherapy. At the 1-st and 8-th day of treatment cyclophosphan in the dose 750 mg/m², vincristine in the dose 1.4 mg/m² and doxorubicin in the dose 30 mg/m² incubated with 200 ml of autoblood are administrated to patients. From the 1-st to 14-th day of treatment prednisolone is used every day in the therapeutic dose. The treatment course is repeated in 30-35 days depending on blood indices and patient state. The total treatment of courses is 4-5. Method provides reducing cardiotoxicity of doxorubicin and cumulative toxicity of chemopreparations that allows carrying out administration of antitumor chemopreparations in the full volume to patients of elderly age groups.

The method deals with polychemotherapy and is fulfilled by the following technique: it is necessary to carry out blood sampling in these patients at the quantity of 25 ml: during the 1^st d of polychemotherapy one should incubate 5 ml autoblood with 50 mg/sq. m metothrexate, during the 2^nd, 3d, 4^th and 5^th d one should incubate per 5 ml autoblood with 15 mg/sq. m bleomycin daily in thermostat at 37 C for 30 min, carry out application anesthesia and introduce chemopreparations upon autoblood into endonasal tumor component or alternate intratumor introduction of chemopreparations upon autoblood at introducing them into maxillary antrum if it is affected with tumor process. The method provides local concentration and decreased toxicity of chemopreparations due to their intratumor introduction upon autoblood.

The present innovation deals with treating elderly patients with chronic lympholeukosis accompanied with cardiovascular failure. The method deals with applying chemopreparations and cytoprotector. Moreover, 1 wk before the onset of chemotherapeutic therapy one should prescribe preductal at the dosage of 105 mg daily. At this background one should sample blood out of elbow vein at the volume of 200 ml into a vial with glugicir to centrifuge it, isolate plasma, divide into two portions, add into the 1^st vial - cyclophosphan 600-800 mg/sq. m, vincristin 1.4 mg/sq. m, into the 2^nd vial - adriamycin 50 mg/sq. m to be incubated for 30 min at 37 C and intravenously injected by drops for patients. Simultaneously, the intake of prednisolone should be prescribed at the dosage of 60 mg/sq. m since the 1^st d and during the next 5 d and preductal at the dosage of 105 mg daily during a week, and then 2 wk more at the dosage of 60 mg daily. All the procedures should be repeated in above-mentioned sequence 4-6 times. The method enables to decrease toxic manifestations of chemotherapy while applying adequate dosages of cytostatics, anthracycline antibiotics, among them, at no great manifestations of their toxicity due to preductal's cardioprotective action.

One should introduce heparin into plasma separated during plasmapheresis at 9000-11000 U/l plasma to incubate it at 4-6 C for 12 h, not less, separate precipitate due to plasma centrifuging at 7-9 C for 15-25 min and introduce the rest plasma into patient's blood. Such procedures should be carried out every other day 5-7 times. The present innovation enables to decrease glomerulosclerosis progressing, avoid excessive heparinization and heparinization-associated complications and, also, those associated with introduction of donor's plasma.

Method involves exposing erythrocytic mass, produced in apparatus, to ultraviolet radiation of wavelength equal to 256 nm produced with a lamp source operating during 15-20 min. Then it is modified with an antibiotic and returned to patient.

Method involves surgery treatment and chemotherapy. In preoperative period 150 ml of blood is taken off in patients, blood is centrifuged for separating for plasma and formed elements. Standard dose of cytostatic agent is separated and placed into the first flask with 20-40 ml of autoplasma and remained plasma part and formed elements are placed into the second flask. Flasks are incubated separately for 40 min at 37°C followed by carrying out a procedure when blood incubated with the chemopreparation from the second flask is administrated by intravenous route by drops. After removing tumor its bed in infiltrated with autoplasma incubated with the chemopreparation from the first flask or autoplasma with the chemopreparation are added in blood vessels in zone of regional blood supply of tumor. Method provides reducing frequency of topical relapses and alienated metastasis after surgery treatment of solid tumors and shows low toxicity. Invention can be used in the complex cancer treatment, in particular, regionally distributed cancer in large intestine and mammary glands.

Invention relates to biological and medical areas and can be used for treatment of biological fluids. Sorbent contains nucleus of ferromagnetic with mono- or bilayer envelop or without thereof. Nucleus is made in the form of plate 500 to 5000 μm in size across its plane and with thickness from 0.1 to 1000 μm. Method for manufacture of sorbent is characterized by that powder of iron and/or nickel, and/or titanium, and/or tantalum is vaporized in low-temperature plasma to form product, which is cooled and condensed in gas flow, condensed product is transferred into stabilized dispersion medium. Resulting crystals and microingots are treated to form plates with desired thickness, which are rinsed with distilled water. Weak parts of plates are detached, affected by ultrasound, and dried. Dried plates are fractioned and sorbent nuclei with desired size are isolated and then are layer-by-layer enveloped.

One should perform blood exfusion at the quantity of 500-550 ml. Removed blood volume should be compensated with crystalloids at the ratio of 1:1.2 - 1: 1.3. Erythrocytic mass should be supplemented with 5-10 ml "Essentiale" solution. This mass should be introduced for a patient at simultaneous ultraviolet blood irradiation for 20-30 min. Plasmapheresis in combination with ultraviolet blood irradiation should be carried out every other day, about 2-4 seances/course, totally. The method provides normalized level of blood leukocytes and body detoxication, it, also, excludes prophylactic course of antibioticotherapy that enables to continue terms of therapy and not to decrease the dosages of chemoradiation therapy.

The method deals with applying chemopreparations incubated with autolymph and radiation therapy. Lymph taken out of patient's thoracic duct should be centrifuged for 30 min at 2200 rot./min, lymphatic plasma should be taken and frozen at -40 C, lymphatic formic elements should be incubated in a thermostat at 37 C for 1 h together with chemopreparations by a certain scheme to be reinfused for a patient intravenously by drops according to the given scheme. Then, 2 wk later, one should perform therapy with a split course of distance gammatherapy at single focal dosage (SFD) of 4 Gy. At the first stage one should apply per 2 Gy twice daily at 4-5-h-long interval 5 times weekly, at achieving focal dosage of 28 Gy it is necessary to have a week-long interval. Then radiation therapy should be continued but SFD of 4 Gy should be applied at once. One should fulfill 3 fractions of irradiation per a week, there are 6 fractions during the second stage, totally. Total focal dosage (TFD) per the whole course of irradiation corresponds to 52 Gy. About 4 wk after radiation therapy one should defrost lymphatic plasma to incubate it with the same chemopreparations in a thermostat at 37 C for 1 h to be then reinfused for a patient intravenously by drops. The method enables to decrease tumor volume and tumor process metastasing without any operative interference.